1. Home
  2. CHNR vs DRMA Comparison

CHNR vs DRMA Comparison

Compare CHNR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Natural Resources Inc.

CHNR

China Natural Resources Inc.

N/A

Current Price

$4.08

Market Cap

5.0M

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

BUY

Current Price

$1.41

Market Cap

5.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CHNR
DRMA
Founded
N/A
2014
Country
China
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
5.6M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
CHNR
DRMA
Price
$4.08
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
10.7K
394.5K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$0.95
52 Week High
$8.20
$6.22

Technical Indicators

Market Signals
Indicator
CHNR
DRMA
Relative Strength Index (RSI) 56.90 63.39
Support Level $3.93 $1.14
Resistance Level $4.25 $1.84
Average True Range (ATR) 0.18 0.12
MACD 0.05 0.02
Stochastic Oscillator 72.21 87.83

Price Performance

Historical Comparison
CHNR
DRMA

About CHNR China Natural Resources Inc.

China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: